Kailera Therapeutics Inc.’s “obesity-first” approach continues to resonate with investors, with the company pricing an upsized IPO, offering 39 million shares at $16 apiece for gross proceeds of $625 ...
Researchers from the Government College University Faisalabad reported the discovery and preclinical characterization of IMS-48, a benzimidazole analogue designed to inhibit both acetylcholinesterase ...
Cisplatin is widely used in chemotherapy regimens for many solid tumors, yet its therapeutic benefit is counterbalanced by significant toxicity and immunologically related limitations. Researchers ...
Syracuse University recently presented a comprehensive preclinical program describing the rational design and optimization of peptide antagonists targeting the GDF15/GFRAL/RET receptor complex to ...
RNA epigenetics specialist Storm Therapeutics Ltd. has closed a $56 million series C to fund phase II development of its lead RNA enzyme inhibitor, STC-15, in treating myo- and liposarcomas, and ...
Recent evidence has suggested that secreted L-amino-acid oxidase, also known as interleukin-4-induced protein 1 (IL4I1), is involved in aromatic amino acid metabolism, as a key immunosuppressive ...
Co. Ltd. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a cyclin-dependent kinase 4 (CDK4)- and/or CDK4/6 ...
Co. Ltd. patent details new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 1 (IRAK-1)- and ...
Roche Holding AG is making good on its promise to try and convince the EMA of the benefits of Elevidys (delandistrogene ...
The ability of Ebenbuild GmbH’s digital twin technology to predict the deposition of inhaled drugs across the lungs has been ...
Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on ...
Co. Ltd. has patented new 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives acting as thyroid hormone receptor β (THR-β) agonists potentially useful for the treatment of diabetes, obesity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results